Nicotine Gum Recovery After Colorectal Surgery

NCT ID: NCT01662115

Last Updated: 2017-08-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate whether the use of nicotine gum in the postoperative period influences surgical outcome in patients undergoing colorectal surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main hypothesis of this study is that use of nicotine gum after colorectal surgery will accelerate recovery of bowel function. Eligible patients include all patients undergoing segmental small bowel or large bowel resection with a planned primary anastomosis, planned removal of the nasogastric tube at the end of the surgery, and administration of clear liquids on post-operative day one. Patients who have an ileostomy or colostomy created will be excluded. Patients enrolled in the study will be randomized to one of three groups: nicotine gum, regular gum, or no gum. Patients randomized to nicotine gum or regular gum will chew the gum three times a day for 1 week. The main outcome measure is time to first bowel movement or flatus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-operative Ileus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nicotine gum

100 subjects who will actually get the intervention medication

Group Type ACTIVE_COMPARATOR

Nicotine gum

Intervention Type DRUG

Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first

regular chewing gum

100 subjects who will be part of a control group

Group Type SHAM_COMPARATOR

Regular chewing gum

Intervention Type OTHER

Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first

No gum

100 subjects who will not get neither the intervention nor the placebo gum.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicotine gum

Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first

Intervention Type DRUG

Regular chewing gum

Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nicorrete gum Sugarlees chewing gum

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to freely give written informed consent to participate in the study and have signed the Informed Consent Form;
* Due to undergo small and/or large partial bowel resection via laparotomy or laparoscopy;

Exclusion Criteria

* Prior intestinal surgery
* Mentally incompetent or unable or unwilling to provide informed consent or comply with study procedures
* American Society of Anesthesiologists (ASA) Class IV or V;
* History of abdominal carcinomatosis;
* History of radiation enteritis;
* Children \< 18 or adults \> 85 years of age
* Pregnant women
* Current cigarette, cigar smokers and chewers of tobacco. ex smokers who quit less than 3 months ago.
* Patients requiring postoperative ventilation, pressor requirement or ICU stay
* Patients with prior cardiovascular disorders
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Cleveland Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eric Weiss

DIO and Chairman of Graduate Medical Education at Cleveland Clinic Florida,

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ERIC G WEISS, MD

Role: PRINCIPAL_INVESTIGATOR

Cleveland Clinic Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cleveland Clinic Florida

Weston, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRS-2012-05

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.